Romero Jiménez, Rosa María
Herranz Pinto, Pedro
Campos Domínguez, Minia
Aceituno Mata, Susana
Bellmunt, Alba
Prades, Miriam
Arumi, Daniel
Hernández-Martín, Irene
Herrera-Lasso, Valeria
Llevat, Noelia
De Lossada Juste, Alfonso
Rebollo Laserna, Francisco José http://orcid.org/0000-0003-3651-3687
Funding for this research was provided by:
Pfizer
Article History
Accepted: 22 November 2023
First Online: 18 January 2024
Declarations
:
: This study was sponsored by Pfizer, S.L.U., Spain.
: This analysis was sponsored by Pfizer, S.L.U., Spain. Arumi, Hernández-Martín, Herrera-Lasso, Llevat, De Lossada Juste, and Rebollo Laserna are employees of Pfizer (Spain). Aceituno Mata, Bellmunt, and Prades disclose that they are paid consultants to Outcomes10, a company paid by Pfizer to assist with the writing of this manuscript. Herranz Pinto has served as investigator and/or speaker for Abbvie, Almirall, Bristol Myers Squibb, Janssen, Leopharma, Lilly, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, and UCB pharma. Campos Dominguez has served as speaker for Sanofi and Abbvie and as investigator for Abbvie. Romero Jimenez declares no conflicts of interest.
: Data are available from the corresponding author upon reasonable request.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
: RMRJ, PHP, MCD validated the parameters and provided data about local management of patients. SAM, AB and MP performed the analysis. All authors participated in the interpretation of the results. The first draft of the manuscript was primarily written by SAM and AB, and all authors provided comment and revision on subsequent versions of the manuscript. All authors reviewed and approved the final manuscript.